PressJune 3, 2024 Numinus Wellness Announces Voting Results From its Annual General Meeting of Shareholders
PressMay 31, 2024 atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
Health & ScienceMay 31, 2024 FSD Pharma Triumphs in Legal Dispute Against Former CEO Dr. Raza Bokhari
Health & ScienceMay 31, 2024 FTC’s Final Rule Amendment to the Health Breach Notification Rule and Its Implications
LifestyleMay 30, 2024 Webinar: Analyzing the FDA Advisory Committee Review of MDMA-Assisted Therapy for PTSD
PressMay 30, 2024 Numinus and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder
PressMay 30, 2024 Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
PressMay 30, 2024 Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors
PressMay 30, 2024 Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy
PressMay 29, 2024 Red Light Holland Initiates Psilocybin Extraction Phase with PharmAla Following Successful Testing and Preparation by CCrest Labs
PressMay 29, 2024 Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
PressMay 29, 2024 Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
PressMay 24, 2024 Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of Re104 for Development in Depressive Disorders
PressMay 23, 2024 atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
PressMay 23, 2024 Pharmadrug’s Securedose Announces LOI with Canadian Controlled Drug Substance Licensed Dealer for Patent Pending Pharmaceutical Grade Cocaine
PressMay 23, 2024 PharmAla CEO Nick Kadysh Pens Op-ed: Mental Health in Crisis, MDMA May Be the Prescription
